• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Urinary Tract Infections (UTI) Therapeutics - Pipeline Assessment and Market Forecasts to 2018 - Product Image

Urinary Tract Infections (UTI) Therapeutics - Pipeline Assessment and Market Forecasts to 2018

  • ID: 2114325
  • February 2012
  • 72 pages
  • GlobalData

FEATURED COMPANIES

  • AstraZeneca PLC
  • Cubist Pharmaceuticals
  • Forest Laboratories
  • MORE

Urinary Tract Infections (UTI) Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Summary

GlobalData, the industry analysis specialist, has released its new report, “Urinary Tract Infections (UTI) Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global Urinary Tract Infections Therapeutics market. The report identifies the key trends shaping and driving the global Urinary Tract Infections Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Urinary Tract Infections Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Scope

The report provides information on the key drivers and challenges of the Urinary Tract Infections Therapeutics market. Its scope READ MORE >

FEATURED COMPANIES

  • AstraZeneca PLC
  • Cubist Pharmaceuticals
  • Forest Laboratories
  • MORE

1
1

1.1 List of Tables
1.2 List of Figures
2 UTI Therapeutics - Introduction
2.1 Overview
2.2 Classification of UTI
2.2.1 Site of Infection
2.2.2 Based On Symptoms
2.2.3 Based on Recurrence
2.2.4 Based on Complicating Factors
2.2.5 Based on Origin of Infection
2.3 Epidemiology
2.4 Etiology
2.5 Risk Factors
2.6 Signs and Symptoms
2.7 Pathophysiology of UTI
2.8 Diagnosis and Treatment of UTI
2.9 GlobalData Pipeline Report Guidance
3 UTI Therapeutics - Market Characterization
3.1 UTI Therapeutics Market Size (2005-2010) - Global
3.2 UTI Therapeutics Market Forecast (2010-2018) - Global
3.3 UTI Therapeutics Market Size (2005-2010) - The US
3.4 UTI Therapeutics Market Forecast (2010-2018) - The US
3.5 UTI Therapeutics Market Size (2005-2010) - France
3.6 UTI Therapeutics Market Forecast (2010-2018) - France
3.7 UTI Therapeutics Market Size (2005-2010) - Germany
3.8 UTI Therapeutics Market Forecast (2010-2018) - Germany
3.9 UTI Therapeutics Market Size (2005-2010) - Italy
3.10 UTI Therapeutics Market Forecast (2010-2018) - Italy
3.11 UTI Therapeutics Market Size (2005-2010) - Spain
3.12 UTI Therapeutics Market Forecast (2010-2018) - Spain
3.13 UTI Therapeutics Market Size (2005-2010) - The UK
3.14 UTI Therapeutics Market Forecast (2010-2018) - The UK
3.15 UTI Therapeutics Market Size (2005-2010) - Japan
3.16 UTI Therapeutics Market Forecast (2010-2018) - Japan
3.17 Drivers and Barriers for the UTI Therapeutics Market
3.17.1 Drivers for the UTI Therapeutics Market
3.17.2 Barriers for the UTI Therapeutics Market
3.18 Key Events Impacting the Future Market
3.19 Opportunity and Unmet Need
3.20 Key Takeaway
4 UTI Therapeutics Market - Competitive Assessment
4.1 Overview
4.1.1 Strategic Competitor Assessment
4.2 Profiles of Commonly Used Products in the UTI Therapeutics Market
4.2.1 Ciprofloxacin
4.2.2 Doribax (doripenem)
4.2.3 Invanz (ertapenem sodium)
4.2.4 Levaquin (levofloxacin)
4.2.5 Fosfomycin tromethamine
4.2.6 Macrobid/Macrodantin (nitrofurantoin)
4.2.7 Bactrim/Septra (trimethoprim/sulfamethoxazole)
4.3 Key Takeaway
5 UTI Therapeutics Market - Pipeline Assessment
5.1 Overview
5.2 Strategic Pipeline Assessment
5.2.1 UTI Therapeutics - Phase III Pipeline
5.2.2 UTI Therapeutics - Phase II Pipeline
5.2.3 UTI Therapeutics – Phase I Pipeline
5.3 UTI Pipeline by Mechanism of Action
5.4 UTI Technology Trends Analytical Framework
5.5 UTI Therapeutics - Late-stage Drugs under Clinical Development
5.6 Molecule Profile for Late-stage Drugs under Clinical Development
5.6.1 CXA-201 (CXA-101/tazobactam)
5.6.2 CAZ-AVI (Avibactam/ceftazidime)
5.7 Key Takeaway
6 UTI Therapeutics - Clinical Trials Mapping
6.1 Clinical Trials by Country (US, EU5 and Japan)
6.2 Clinical Trials by Phase
6.3 Clinical Trials by Trial Status
6.4 Overall Sponsors
6.5 Prominent Sponsors
6.6 Top Companies Participating in UTI Therapeutics Clinical Trials
7 UTI Therapeutics - Strategic Assessment
7.1 UTI Therapeutics - Implications for Future Market Competition
8 UTI Therapeutics - Future Players
8.1 Introduction
8.1.1 AstraZeneca PLC
8.1.2 Cubist Pharmaceuticals
8.1.3 Forest Laboratories
9 UTI Therapeutics - Licensing and Partnership Deals
10 UTI Therapeutics - Appendix
10.1 Definitions
10.2 Acronyms
10.3 Research Methodology
10.3.1 Coverage
10.3.2 Secondary Research
10.3.3 Forecasting
10.3.4 Primary Research
10.3.5 Expert Panel Validation
10.4 Contact Us
10.5 Disclaimer
10.6 Bibliography

1.1 List of Tables
Table 1: UTI - Prevalence, Major Markets, 2010
Table 2: UTI Therapeutics Market, Global, Revenue ($bn), 2005-2010
Table 3: UTI Therapeutics Market, Global, Forecast ($bn), 2010-2018
Table 4: UTI Therapeutics Market, The US, Revenue ($m), 2005-2010
Table 5: UTI Therapeutics Market, The US, Forecast ($bn), 2010-2018
Table 6: UTI Therapeutics Market, France, Revenue ($m), 2005-2010
Table 7: UTI Therapeutics Market, France, Forecast ($m), 2010-2018
Table 8: UTI Therapeutics Market, Germany, Revenue ($m), 2005-2010
Table 9: UTI Therapeutics Market, Germany, Forecast ($m), 2010-2018
Table 10: UTI Therapeutics Market, Italy, Revenue ($m), 2005-2010
Table 11: UTI Therapeutics Market, Italy, Forecast ($m), 2010-2018
Table 12: UTI Therapeutics Market, Spain, Revenue ($m), 2005-2010
Table 13: UTI Therapeutics Market, Spain, Forecast ($m), 2010-2018
Table 14: UTI Therapeutics Market, The UK, Revenue ($m), 2005-2010
Table 15: UTI Therapeutics Market, The UK, Forecast ($m), 2010-2018
Table 16: UTI Therapeutics Market, Japan, Revenue ($m), 2005-2010
Table 17: UTI Therapeutics Market, Japan, Forecast ($m), 2010-2018
Table 18: UTI Therapeutics - Phase III Pipeline
Table 19: UTI Therapeutics - Phase II Pipeline
Table 20: UTI Therapeutics – Phase I Pipeline
Table 21: UTI Therapeutics - Late-stage Drugs Under Clinical Development, 2011
Table 22: UTI Therapeutics - Clinical Trials by Country, 2011
Table 23: UTI Therapeutics - Clinical Trials by Phase, 2011
Table 24: UTI Therapeutics - Clinical Trials by Status, 2011
Table 25: UTI Therapeutics, Overall Sponsors, 2011
Table 26: UTI Therapeutics - Prominent Sponsors, 2011
Table 27: UTI Therapeutics - Top Companies Participating in Clinical Trials, 2011
Table 28: AstraZeneca Infectious Disease Pipeline, 2011
Table 29: Cubist Pharmaceuticals Infectious Disease Pipeline, 2011
Table 30: Forest Laboratories - Infectious Disease Pipeline, 2011
Table 31: Licensing and Partnership Deals

1.2 List of Figures
Figure 1: Classification of UTI
Figure 2: Principal Pathogens of UTI
Figure 3: Symptoms of UTI
Figure 4: Diagnostic Approach to UTI in Adults
Figure 5: Different Class of Antibiotics Used for UTI
Figure 6: Diagnosis and Treatment of UTI
Figure 7: Diagnosis and Treatment of UTI
Figure 8: UTI Therapeutics Market, Global, Revenue ($bn), 2005-2010
Figure 9: UTI Therapeutics, Market Share ($m, %), 2010
Figure 10: UTI Therapeutics Market, Global, Forecast ($bn), 2010-2018
Figure 11: UTI Therapeutics, Market Share ($m, %), 2018
Figure 12: UTI Therapeutics Market, The US, Revenue ($m), 2005-2010
Figure 13: UTI Therapeutics Market, The US, Forecast ($bn), 2010-2018
Figure 14: UTI Therapeutics Market, France, Revenue ($m), 2005-2010
Figure 15: UTI Therapeutics Market, France, Forecast ($m), 2010-2018
Figure 16: UTI Therapeutics Market, Germany , Revenue ($m), 2005-2010
Figure 17: UTI Therapeutics Market, Germany, Forecast ($m), 2010-2018
Figure 18: UTI Therapeutics Market, Italy, Revenue ($m), 2005-2010
Figure 19: UTI Therapeutics Market, Italy, Forecast ($m), 2010-2018
Figure 20: UTI Therapeutics Market, Spain, Revenue ($m), 2005-2010
Figure 21: UTI Therapeutics Market, Spain, Forecast ($m), 2010-2018
Figure 22: UTI Therapeutics Market, The UK, Revenue ($m), 2005-2010
Figure 23: UTI Therapeutics Market, The UK, Forecast ($m), 2010-2018
Figure 24: UTI Therapeutics Market, Japan, Revenue ($m), 2005-2010
Figure 25: UTI Therapeutics Market, Japan, Forecast ($m), 2010-2018
Figure 26: UTI Therapeutics Market , Key Events Impacting the Future Market
Figure 27: Opportunity and Unmet Need in the UTI Therapeutics Market, 2011
Figure 28: UTI Therapeutics - Strategic Competitor Assessment, 2011
Figure 29: UTI Therapeutics - Pipeline by Phase of Clinical Development, 2011
Figure 30: UTI Therapeutics Market - Clinical Pipeline by Mechanism of Action, 2011
Figure 31: Technology Trends Analytical Framework of the UTI Pipeline, 2011
Figure 32: Technology Trends Analytical Framework of The UTI Therapeutics Pipeline - Description, 2011
Figure 33: UTI Therapeutics - Clinical Trials by Country, 2011
Figure 34: UTI Therapeutics - Clinical Trials by Phase, 2011
Figure 35: UTI Therapeutics - Clinical Trials by Status, 2011
Figure 36: UTI Therapeutics - Overall Sponsors, 2011
Figure 37: UTI Therapeutics - Prominent Sponsors, 2011
Figure 38: UTI Therapeutic Clinical Trial - Company Sponsors by Phase, 2011
Figure 39: Implications for Future Market Competition in the UTI Therapeutics Market, 2011
Figure 40: UTI Therapeutics Market - Clinical Pipeline by Company, 2011
Figure 41: GlobalData Market Forecasting Model

FEATURED COMPANIES

  • AstraZeneca PLC
  • Cubist Pharmaceuticals
  • Forest Laboratories
  • MORE

GlobalData, the industry analysis specialist, has released its new report,”‘Urinary Tract Infections (UTI) Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global UTI therapeutics market. The report identifies the key trends shaping and driving the global UTI therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global UTI therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

The UTI Therapeutics Market is Forecast to Show Moderate Growth until 2018

GlobalData estimates that the global Urinary Tract Infections (UTI) therapeutics market was worth $1.6 billion in 2010, which grew at a compound annual growth rate (CAGR) of 6.9% from $1.2 billion in 2005. This high growth rate, during the period 2005-2010, was primarily attributed to the increase in uptake of premium priced antibiotics such as Levaquin (levofloxacin) and Doribax (doripenem) for the treatment of UTI and the increase in the prevalence and diagnosis of UTI. The UTI therapeutics market is forecast to show moderate growth, at a CAGR of 2.3% for the next eight years, to reach $1.9 billion by 2018. This reduced growth will come as a result of the patent expiries of Invanz (ertapenem) and Doribax and the subsequent launch of generics in the forecast period. The expected launch of late stage pipeline molecules in the forecast period will offset generic incursion and drive the market.

The UTI Therapeutics Market has Low Unmet Need

The UTI therapeutics market is well-served by the current marketed products, which have strong efficacy and safety profiles. However, most of the surveillance studies showed that many bacterial species have developed resistance to older antibiotics. Antibiotic resistance to the current market products necessitates the introduction of novel antibiotics that treat resistant strains and this offers adequate opportunity for new formulations and fixed dose combinations of available products with improved bioavailability, longer half-lifes and better pharmacokinetic performance.

Competition Among Marketed Products is Strong in the UTI Therapeutics Market

GlobalData analyzed the current competitive landscape for UTI therapeutics market and found that current competition in the UTI therapeutics market is strong. Almost all marketed products have strong efficacy and safety profiles. There are more than seven classes of antibiotics used for the treatment of UTI. Fluoroquinolones have emerged as the most prescribed antibiotics for UTIs due to their superior efficacy and safety profiles. They have replaced trimethoprim/sulfamethoxazole as the first-choice treatment option, despite the latter being the recommended therapeutic option in the guidelines of major international institutions. In addition, levofloxacin, the most commonly prescribed fluoroquinolone, followed by ciprofloxacin, is available as a low cost generic, which has further increased competition in the UTI therapeutics market.

AstraZeneca PLC
Cubist Pharmaceuticals
Forest Laboratories

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos